Supernus v. Macleods: Qelbree® Viloxazine Patents Consolidated in D.N.J.
Supernus Pharmaceuticals filed suit against Macleods Pharmaceuticals in the District of New Jersey, asserting six Orange Book-listed patents covering Qelbree® (viloxazine extended-release capsules). After just 105 days, the case was consolidated with 13 co-defendants into a single pretrial proceeding — signalling a broad, coordinated ANDA defence challenge.
Six-Patent Qelbree® ANDA Battle Draws 13 Generic Challengers
Supernus Pharmaceuticals filed Case No. 2:25-cv-15399 in the District of New Jersey on 9 September 2025, asserting infringement of six Orange Book-listed patents — US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — all covering Qelbree® (viloxazine hydrochloride extended-release capsules, 100 mg, 150 mg, and 200 mg). The suit arose from Macleods Pharmaceuticals’ ANDA filing seeking FDA approval for a generic version of Qelbree®.
On 23 December 2025, following an Initial Scheduling Conference on 17 December 2025, the Court directed Supernus and all named defendants to submit a proposed Consolidation Order. The case was formally closed at the individual docket level and folded into a consolidated multi-defendant proceeding for pretrial purposes, with the schedule anchored to Civil Action No. 25-12183. No merits determination was reached; the consolidation is a procedural efficiency measure, not a resolution of the underlying infringement claims.
The 105-day period from filing to consolidation is consistent with standard Hatch-Waxman ANDA case management practice in D.N.J., where courts routinely consolidate parallel ANDA cases involving the same reference listed drug. The breadth of the defendant roster — 13 generic manufacturers including Apotex, Aurobindo, Zydus, and MSN — suggests coordinated ANDA filings, which typically signals that the 30-month stay clock will be a central strategic variable. The public record does not yet disclose claim construction positions, invalidity contentions, or any licensing discussions.
Filing to Case Consolidated in 105 days
105-day docket lifespan before consolidation — faster than the typical 18–24 month ANDA trial track
Case consolidated: what this means for the Qelbree® ANDA litigation
Consolidation under Rule 42 — one docket, shared pretrial schedule
Federal Rule of Civil Procedure 42(a) permits a court to consolidate cases sharing common questions of law or fact. Here, the Court directed all Qelbree® ANDA defendants — including Macleods — onto a single pretrial schedule anchored to Case No. 25-12183. Individual case numbers are formally closed at the docket level, but no claim has been dismissed and no merits ruling has been made. Consolidation is an efficiency tool, not an outcome.
Procedural consolidationSupernus gains unified enforcement leverage across 13 defendants
Consolidation is broadly favourable for a branded plaintiff managing multi-defendant ANDA litigation. Supernus can coordinate claim construction, expert witnesses, and discovery across all challengers simultaneously, reducing per-defendant costs. The six asserted patents remain in force and enforceable. The 30-month stay triggered by the Hatch-Waxman filing continues to run, protecting Qelbree® market exclusivity while litigation proceeds on the consolidated track.
Plaintiff: exclusivity protectedMacleods faces a shared defence — and shared exposure — with 12 co-defendants
Macleods’ individual case is now subsumed into a consolidated proceeding with 12 other generic manufacturers. While shared resources may reduce individual litigation costs, defendants’ invalidity and non-infringement positions must be coordinated, which can limit strategic flexibility. Any adverse claim construction ruling will apply across all defendants simultaneously, raising the collective stakes of each pretrial decision.
Defendant: coordinated defenceQelbree® market entry timeline now hinges on a single consolidated outcome
With 13 generic challengers consolidated before one judge, the commercial fate of viloxazine ER generics will likely be decided in a single trial or global settlement. A Supernus win on any of the six patents could delay all generic entry. A successful invalidity challenge by even one defendant could benefit the entire generic field. Stakeholders monitoring Qelbree® market access should track the consolidated docket in Case No. 25-12183.
Market entry: watch lead docketFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Supernus Pharmaceuticals, Inc. | Company | Specialty CNS pharmaceutical company — holder of US12121523B2 and 5 further Qelbree® patentsSearch in Eureka ↗ |
| Defendant | Macleods Pharmaceuticals | Individual | Indian generic pharmaceutical manufacturer seeking FDA ANDA approval for viloxazine ER capsulesSearch in Eureka ↗ |
| Plaintiff counsel | Alexander Lee Callo | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EDGAR H. HAUG | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JONATHAN HERSTOFF | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | KAITLIN M. FARRELL | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | NICHOLAS F. GIOVE | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Richard Frank Kurz | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William C. Baton | Attorney | Counsel for Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Haug Partners, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Saul Ewing, LLP | Law Firm | Representing Supernus Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | COREY WEINSTEIN | Attorney | Counsel for Macleods PharmaceuticalsSearch in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Macleods PharmaceuticalsSearch in Eureka ↗ |
| Defendant counsel | NEAL SETH | Attorney | Counsel for Macleods PharmaceuticalsSearch in Eureka ↗ |
| Defendant law firm | COUNSEL NOT ADMITTED TO USDC – NJ BAR | Law Firm | Representing Macleods PharmaceuticalsSearch in Eureka ↗ |
| Defendant law firm | Counsel Not Admitted To Usdc (NJ BAR) | Law Firm | Representing Macleods PharmaceuticalsSearch in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Macleods PharmaceuticalsSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order as recited in the verdict language is purely procedural — the Court made no findings on infringement, validity, or claim construction. The phrasing confirms that all named defendants, including Macleods, remain active parties in the consolidated proceeding. No claims were dismissed with or without prejudice. The operative litigation schedule is now governed by the lead docket (Case No. 25-12183), and this individual case number functionally serves as a placeholder record.
US12121523B2 — Viloxazine Extended-Release Capsule Formulations
The six asserted patents — US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — collectively define a patent family protecting the formulation, composition, and methods of use of viloxazine hydrochloride in extended-release capsule form, marketed as Qelbree®. The earlier patents (US9358204B2, US9603853B2, US9662338B2) carry priority dates suggesting foundational composition and formulation claims, while the later patents (US11324753B2, US11458143B2, US12121523B2) likely represent continuation coverage targeting refined dosage forms and therapeutic methods for ADHD treatment.
All six patents are listed in the FDA’s Orange Book for Qelbree®, giving each one independent Hatch-Waxman significance: any ANDA filer must certify against each, triggering potential 30-month stay protection per certification. For CNS drug manufacturers and generic entrants, this patent cluster represents a durable exclusivity barrier for viloxazine ER. Competitors developing non-stimulant ADHD therapies or extended-release CNS formulations should assess claim scope carefully — particularly the method-of-use patents, which may capture therapeutic dosing protocols independently of formulation design-arounds.
Should you run an FTO against US12121523B2 and the Qelbree® patent family?
Any pharmaceutical company developing a viloxazine hydrochloride extended-release product — or a structurally related non-stimulant ADHD therapy in an ER capsule format — should conduct a full FTO assessment against all six Orange Book patents asserted in this case. The breadth of the family (six patents across multiple application generations) means a single-patent clearance is insufficient. Method-of-use claims in particular may cover therapeutic dosing regimens independently of formulation composition.
PatSnap Eureka’s FTO Search Agent can map claim scope across all six patents simultaneously, identify published prior art relevant to invalidity positions, and flag continuation application activity that may produce additional claims. For generic manufacturers already in the consolidated ANDA proceeding, Eureka can support invalidity contention development by surfacing claim-level prior art across the viloxazine and ER capsule formulation literature.
Run a freedom-to-operate analysis on US12121523B2 to assess your product’s exposure
Run FTO in Eureka →Similar Orange Book ANDA Patent Cases in D.N.J. — CNS Formulations
Explore related Hatch-Waxman ANDA patent infringement cases in D.N.J. involving CNS drug extended-release formulations and multi-defendant consolidations.
What this case signals for the CNS ANDA patent IP landscape
A 13-defendant consolidation around six Orange Book patents is a defining pattern in branded CNS drug defence strategy.
Multi-patent Orange Book listing is Supernus’s core defensive architecture
Six Orange Book-listed patents covering a single product — Qelbree® — creates a layered exclusivity wall. Generic challengers must invalidate or design around all six to achieve unencumbered market entry. Each patent represents a separate litigation track and potential 30-month stay trigger, compounding the time and cost burden on ANDA filers.
13-defendant consolidation compresses the timeline but not the complexity
D.N.J. consolidation of ANDA cases with common Orange Book patents is standard practice, but coordinating 13 defendants’ invalidity strategies is operationally complex. Early movers with Para. IV certifications filed before the 30-month stay expiry will be critical to watch — first-to-file 180-day exclusivity rights may further concentrate generic market entry risk.
Supernus v Macleods — key questions answered
Consolidation means the Court merged Case No. 2:25-cv-15399 with related Qelbree® ANDA cases for pretrial purposes under Rule 42(a). No claims were dismissed and no merits ruling was made. Macleods remains an active defendant in the lead consolidated proceeding, Case No. 25-12183.
Supernus asserted six Orange Book-listed patents: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2. All cover aspects of viloxazine hydrochloride extended-release capsule formulations and methods of use for Qelbree® (100 mg, 150 mg, 200 mg).
The consolidation order named 13 defendant groups including Macleods Pharmaceuticals, Appco Pharma, Somerset Therapeutics, Apotex, Aurobindo Pharma, Zydus Lifesciences, Creckwood Pharmaceuticals, MSN Pharmaceuticals, Zenara Pharma, and Biophore Pharma, among others.
The case arises from ANDA filings against six Orange Book-listed patents, consistent with Hatch-Waxman litigation. The 30-month stay, triggered upon timely filing of an infringement suit after a Para. IV certification, typically applies in such proceedings. The public record does not specify the exact stay expiry date for each defendant.
Qelbree® (viloxazine hydrochloride extended-release capsules) is Supernus’s branded non-stimulant ADHD treatment. Its commercial success has made it a target for generic entry by multiple ANDA filers. The six Orange Book patents listed for Qelbree® must each be addressed by any generic seeking FDA approval, driving the multi-defendant litigation landscape.
PatSnap Eureka searches patents and litigation data to answer instantly.